NIH, right? You list only the applicant organization's F & A rate. In
most collaborative arrangements, the subawardees are pretty much
invisible to the sponsor; the condition of "privity" (hope I'm using
this correctly) exists between the sponsor and the applicant
organization, not between the sponsor and subawardees.
PJD
****************************************************************
Peter J. Dolce, Ph.D.
Associate Vice President for Research
Grants Management and Compliance
1005 D. B. Todd Boulevard
Meharry Medical College
Phone 615 327 6225
Fax 615 327 6716
Nashville, TN 37208
-----Original Message-----
From: Research Administration List [mailto:xxxxxx@HRINET.ORG] On
Behalf Of Robert Miller
Sent: Thursday, August 18, 2005 12:40 PM
To: xxxxxx@HRINET.ORG
Subject: [RESADM-L] Checklist / F&A costs
Master-budgeteers...
One of my PI's seems to think that when completing the checklist (non
competing continuation) you must separately list the F&A of the
consortium contract (on the check list). I disagree, the instructions
does not state so as the direct costs of the primary encompasses the
F&A of the consortium contract.
Your input would help.
Thanks
Robert Gregory Miller
Charles R. Drew University of Medicine and Science
Div. of Endocrinology, Metabolism and Molecular Science
Administrative Director/Research Administrator
xxxxxx@cdrewu.edu
Office: 323.563.5961
Fax: 323.563.5966
Notice of Confidentiality
This message contains information that may be confidential or
privileged.
It is intended for the exclusive use of the addressee or any person
entitled to receive it. If you received this message in error,
please inform the author as soon as possible, do not disclose its
contents and delete it from your system
======================================================================
Instructions on how to use the RESADM-L Mailing List, including
subscription information and a web-searchable archive, are available
via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================
DISCLAIMER: This email and any files transmitted with it may be privileged, confidential, and contain health information that is legally protected. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless permitted to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any use, disclosure, copying, or distribution, is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents.
======================================================================
Instructions on how to use the RESADM-L Mailing List, including
subscription information and a web-searchable archive, are available
via our web site at http://www.hrinet.org (click on "Listserv Lists")
======================================================================
